Perficient: Drug Development

FEBRUARY 27, 2024

Imagine this: You are a marketer at a medical device organization. It’s every marketer’s dream. Let’s look at a few ways medical device marketers can supercharge the digital product catalogs. Perhaps there is a text-based testimonial by a loyal user or a video giving a glimpse of the manufacturing and QA process.

Production 52

Production Testimonials Marketing Science 52

The Pharma Data

MAY 13, 2021

The way this was done, was through webinars. I know you may be asking, “What is a webinar”? A webinar is an online video presentation that is focused on great practical information which you sit back and view on your PC, Mac, iPod or iPad. Plus, most webinars you canâ??t I was at a fitness site and watched a free webinar.

Production 52

Production Treatment Vaccine Therapies 52

Agency IQ

JUNE 29, 2023

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 27, 2023

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. the drug and device) of the combination product. The final rule will amend the administrative destruction provisions in 21 CFR 1.94 to include devices.

FDA 40

FDA Science Regulations Production 40

Agency IQ

SEPTEMBER 29, 2023

Due to the presence of nitrosamines in certain drug products, FDA had required that drug manufacturers conduct an initial risk assessment of approved or marketed products, with an initial completion date of October 1, 2021, and then confirmatory testing due by October 1, 2023. AgencyIQ October 1 Nitrosamine testing due to FDA.

FDA 40

FDA Science Regulations Production 40

Agency IQ

DECEMBER 1, 2023

to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. Prohaska, Kavita C. and Annex 1 Conference Joel Welch December 12 AgencyIQ Looking ahead to 2024: Regulatory Forecast for the U.S. to include devices.

FDA 40

FDA Science Regulations Production 40

Conversations in Drug Development Trends

MARCH 11, 2025

To address these concerns in CAR T therapy trials , Worldwides Dr. Simran Padam, Dr. Amy Raymond, and Nathan Chadwick discussed with Dr. Chris Jenkins of Sabai Global and Dr. Tahseen Mozaffar of UC Irvine in an on-demand webinar, Expanding CAR T Beyond Oncology: Medical, Operational & Practical Considerations.

Clinical Trials 40

Clinical Trials Therapies Trials Treatment 40